Atea Pharmaceuticals, Inc. Operating Income (Loss) in USD from 2018 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Atea Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2018 to Q3 2025.
  • Atea Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2025 was -$45.6M, a 22.5% decline year-over-year.
  • Atea Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2025 was -$165M, a 17.7% increase year-over-year.
  • Atea Pharmaceuticals, Inc. annual Operating Income (Loss) for 2024 was -$193M, a 17.5% decline from 2023.
  • Atea Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$164M, a 25.7% decline from 2022.
  • Atea Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$131M, a 194% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)

Atea Pharmaceuticals, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$165M -$45.6M -$8.37M -22.5% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-12
Q2 2025 -$157M -$41.3M +$5.57M +11.9% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-07
Q1 2025 -$162M -$39M +$30.8M +44.1% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-12
Q4 2024 -$193M -$39M +$7.55M +16.2% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-06
Q3 2024 -$200M -$37.2M +$3.58M +8.79% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-12
Q2 2024 -$204M -$46.9M -$11.7M -33.2% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-07
Q1 2024 -$192M -$69.8M -$28.2M -67.9% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-12
Q4 2023 -$164M -$46.6M -$6.67M -16.7% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-06
Q3 2023 -$157M -$40.8M -$24.5M -151% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$133M -$35.2M -$2.94M -9.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$130M -$41.6M +$606K +1.44% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$131M -$39.9M -$161M -133% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $30.4M -$16.3M +$5.87M +26.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $24.6M -$32.3M -$41M -472% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $65.5M -$42.2M -$72.8M -238% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $138M $121M +$101M +487% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-28
Q3 2021 $37.8M -$22.1M -$4.52M -25.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $42.4M $8.69M +$18.7M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $23.7M $30.7M +$34.7M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$11M $20.6M Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 -$17.6M -$13.9M -368% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$10M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$4.05M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q3 2019 -$3.77M Jul 1, 2019 Sep 30, 2019 10-Q 2020-12-10

Atea Pharmaceuticals, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$193M -$28.8M -17.5% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-06
2023 -$164M -$33.5M -25.7% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-06
2022 -$131M -$269M -194% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-28
2021 $138M +$149M Jan 1, 2021 Dec 31, 2021 10-K 2023-02-28
2020 -$11M +$3.58M +24.5% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 -$14.6M -$5.13M -54.1% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 -$9.48M Jan 1, 2018 Dec 31, 2018 10-K 2021-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.